業 績 一 覧 2025

原著

  1. Takahashi M, Nakamura K, Chiyoda T, Okada C, Nohara S, Takamatsu R, Yanazume S, Kobayashi H, Nishihara H. Transcriptome concordance between borderline tumors and endometrioid carcinoma: An integrative genomic analysis. Cancer Med. 2025 Jan;14(2):e70601.
  2. Kobayashi R, Matsuda S, Nakamura K, Kawakubo H, Ho K, Morimoto Y, Hisaoka K, Hoshi Y, Takeuchi M, Fukuda K, Okui J, Nishihara H, Kitagawa Y. Clinical value of preoperative circulating tumor DNA before surgery in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2025 May;51(5):109625.
  3. Suzuki S, Akahane T, Tanimoto A, Higashi M, Kitazono I, Kirishima M, Nishigaki M, Ikeda T, Kanemitsu S, Nakazawa J, Akahane E, Nishihara H, Uozumi K, Yoshimitsu M, Ishitsuka K, Ueno SI. Comparison of actionable alterations in cancers with kinase fusion, mutation, and copy number alteration. PLoS One. 2025 Jan 23;20(1):e0305025.
  4. Chikaishi Y, Matsuoka H, Sugihara E, Takeda M, Sumitomo M, Yamada S, Inaguma G, Omura Y, Cheong Y, Kobayashi Y, Nakauchi M, Hiro J, Masumori K, Otsuka K, Nishihara H, Suda K, Saya H, Takimoto T. Mutation analysis of TMB-high colorectal cancer: Insights into molecular pathways and clinical implications. Cancer Sci. 2025 Apr;116(4):1082-1093.
  5. So E, Hayashi H, Shimozaki K, Horie S, Kishimoto S, Chida A, Saito Y, Tsugaru K, Hirata K, Tanishima S, Nishihara H, Kanai T, Hamamoto Y. Clinical utility of comprehensive genomic profiling for advanced pancreatic cancer: insights from real-world data analysis. Int J Clin Oncol. 2025 Apr;30(4):728-737.
  6. Nagase Y, Kodama M, Aimono E, Nakamura K, Takamatsu R, Abe K, Yoshimura T, Chiyoda T, Yamagami W, Nishihara H. CXCL9 and CXCL13 shape endometrial cancer immune-activated microenvironment via tertiary lymphoid structure formation. Cancer Sci. 2025 May;116(5):1193-1202.
  7. Kobayashi Y, Suzuki Y, Seishima R, Chikaishi Y, Matsuoka H, Nakamura K, Shigeta K, Okabayashi K, Hiro J, Otsuka K, Uyama I, Saya H, Nishihara H, Suda K, Kitagawa Y. Utility of comprehensive genomic profiling combined with machine learning for prognostic stratification in stage II/III colorectal cancer after adjuvant chemotherapy. Int J Clin Oncol. 2025 May;30(5):926-934.
  8. Kato Y, Seishima R, Hattori K, Kato H, Ishida H, Shigeta K, Okabayashi K, Sugihara E, Takimoto T, Nakamura K, Nishihara H, Saya H, Kitagawa Y. Significance of homologous recombinant deficiency as a biomarker for drug sensitivity in colorectal cancer. Br J Cancer. 2025 Apr;132(6):533-542
  9. Tanaka K, Mochizuki T, Baba S, Kawai S, Nakano K, Tachibana T, Uchimura K, Kato A, Miyayama T, Yamaguchi T, Nishihara H, Terao K, Kato Y. Robust and reproducible human intestinal organoid-derived monolayer model for analyzing drug absorption. Sci Rep. 2025 Apr 3;15(1):11403
  10. Arai M, Tanaka N, Takamatsu K, Murakami T, Mikami S, Imamura T, Nakamura K, Nishihara H, Oya M. Prognostic impact and landscape of cellular CXCR5 chemokine receptor expression in clear-cell renal cell carcinoma. Cancer Immunol Immunother. 2025 Apr 10;74(5):166.
  11. Yoshimura T, Nakamura K, Chiyoda T, Takamatsu R, Kawano R, Aimono E, Kawaida M, Sakai K, Masugi Y, Nishihara H, Yamagami W. Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification. BJC Rep. 2025 May 20;3(1):37.
  12. Imaeda K, Tamura T, Nagai S, Sugihara E, Yamasaki J, Otsuki Y, Nakamura K, Takeda T, Nakamura K, Nogami Y, Tsuji K, Chiyoda T, Kisu I, Kobayashi Y, Banno K, Yamaguchi R, Sakurada K, Saya H, Aoki D, Ahmed AA, Nagano O, Masuda K, Yamagami W. LCN2-mediated ferroptosis resistance in tissue homeostasis and early-stage tumorigenesis of the fallopian tube epithelium. iScience. 2025 May 13;28(6):112654.
  13. Takamatsu R, Nakamura K, Chiyoda T, Tsuji K, Kawano R, Yoshimi N, Yamagami W, Nishihara H. Advancing precision oncology: Whole-exome sequencing in endometrial cancer liquid-based cytology. Arch Pathol Lab Med. 2025 Jun 1;149(6):561-567.
  14. Fukushima T, Nakamura K, Terai H, Ohgino K, Kawano R, Ishikawa M, Emoto K, Takaoka H, Saito A, Ito F, Nukaga S, Ikemura S, Kawada I, Masuda K, Yasuda H, Okita H, Asakura K, Soejima K, Kosaki K, Nishihara H, Fukunaga K. Clinical sequence revealed the prevalence and biological significance of somatic pathogenic variants in thoracic cancer: Implications for germline status. Clin Lung Cancer. 2025 Jul 26(5):407-419.
  15. Hsu CY, Yanagi T, Miyamoto K, Otsuguro S, Maenaka K, Nishihara H, Nakamura H, Takahashi K, Ujiie H. An FDA-approved drug library screening identifies proteasome inhibitors as selective cytotoxic agents for angiosarcoma cells. Br J Cancer. 2025 Jul;133(1):3-13.
  16. Kubota A, Bandoh N, Goto T, Kono M, Sato R, Suzuki S, Sakaue S, Takeda R, Hayashi S, Hayashi M, Araki D, Baba S, Kato Y, Takahara M, Nishihara H, Kamada H. A retrospective study of laryngeal squamous cell carcinoma and the significance of the PIK3CA mutation for survival. Mol Clin Oncol. 2025 Jul 17;23(4):87.
  17. Miyamoto K, Yanagi T, Maeda T, Kitamura S, Nishihara H, Iwamoto R, Takahashi K, Ujiie H. Eribulin inhibits tumor growth of two novel patient-derived xenograft models of Merkel cell carcinoma. J Dermatol Sci. 2025 Aug;119(2):82-89.
  18. Kobayashi Y, Masuda K, Seki T, Kosaka T, Kitago M, Ono I, Misu K, Ueki A, Yoshihama T, Nagayama A, Yasumizu Y, Goto Y, Nakamura K, Yamada M, Yokota M, Uchida S, Takeuchi M, Funakoshi T, Yamagami W. The Keio HBOC Center: A Model of Hereditary Breast and Ovarian Cancer Management. Keio J Med. 2025 Jun 20. Online ahead of print.
  19. Seki T, Kobayashi Y, Masuda K, Nakamura K, Yamada M, Goto Y, Misu K, Ono I, Nagayama A, Hayashida T, Kitagawa Y. Exploring breast cancer risk management in HBOC patients: Image surveillance versus risk-reducing surgery. Keio J Med. 2025 Apr 2. Online ahead of print.
  20. Masuda K, Kobayashi Y, Seki T, Yoshihama T, Nakamura K, Goto Y, Yamada M, Nagayama A, Uchida S, Ono I, Misu K, Yokota M, Yamagami W. Current situation and future directions of risk-reducing salpingo-oophorectomy. Keio J Med. 2025 Mar 22. Online ahead of print.
  21. Abe K, Kitago M, Kobayashi Y, Masuda K, Seki T, Yamada M, Goto Y, Ono I, Misu K, Nakamura K, Kitagawa Y. Pancreatic Cancer in Hereditary Breast and Ovarian Cancer Syndrome: Is Early Detection Possible? Keio J Med. 2025 Apr 19. Online ahead of print
  22. Nakamura K, Masuda K, Seki T, Kitago M, Kosaka T, Goto Y, Yamada M, Misu K, Ono I, Kobayashi Y, Yamagami W. Potential new tumors associated with hereditary breast and ovarian cancer (HBOC) Keio J Med. 2025 Mar 12. Online ahead of print.
  23. Takaoka H, Terai H, Nakamura K, Mizuno T, Kawano R, Emoto K, Kurebayashi Y, Takada N, Hamabe K, Horie K, Ogata A, Kinoshita K, Shigematsu L, Ito F, Okada M, Fukushima T, Nukaga S, Tani T, Ohgino K, Kaseda K, Ikemura S, Yasuda H, Asakura K, Okita H, Nishihara H, Fukunaga K. Clinical application of in-house comprehensive genomic profiling for thoracic cancer: insights from a Japanese hospital. Cancer Sci. 2025 Oct;116(10):2819-2830.
  24. Sogano J, Tamura R, Yo M, Nakamura K, Fukada I, Ueno T, Hino U, Tomioka A, Karatsu K, Nagao A, Ueda R, Nishihara H, Toda M. Genetic and clinical characteristics of cranial nerve schwannoma harboring SH3PXD2A-HTRA1 fusion gene. Acta Neuropathol. 2025 Sep 19;150(1):31.
  25. Chida A, Hayashi H, Ishida N, So E, Kishimoto S, Horie S, Tsugaru K, Matsuda S, Kawakubo H, Nishihara H, Hamamoto Y, Kanai T, Kitagawa Y, Hirata K. Site-specific prevalence of the NFE2L2 mutation in esophageal squamous cell carcinoma. Int J Clin Oncol. 2025 Oct 29.
  26. Yano K, Kaseda K, Nakamura K, Okubo Y, Masai K, Hishida T, Nukaga S, Ohgino K, Terai H, Yasuda H, Kurebayashi Y, Fukunaga K, Nishihara H, Asakura K. Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II-III non-small cell lung cancer. Sci Rep. 2025 Oct 27;15(1):37477.
  27. Bandoh N, Kubota A, Takeda R, Sakaue S, Goto T, Baba S, Hashiba N, Kato Y, Nishihara H. Renal cell carcinoma metastasizing to the cricoid cartilage presenting with subglottic stenosis: a case report and literature review. Ear Nose Throat J. 2025 Nov;104(2_suppl):102S-107S.
  28. Hirano T, Sakai K, Yoshimura T, Chiyoda T, Nakamura K, Aimono E, Kawaida M, Nishihara H, Susumu N, Aoki D, Yamagami W. Prognostic biomarker of fertility-preserving hormonal therapy based on multigene panel testing for endometrial cancer. Cancer Sci. 2025 Nov 9.  Online ahead of print.
  29. Matsui K, Kawakubo H, Matsuda S, Aimono E, Nakamura K, Fukuda K, Nakamura R, Nishihara H, Kitagawa Y. Current status and clinical usefulness of genomic panel testing using PleSSision-160 in resectable esophageal squamous cell carcinoma. Eur J Surg Oncol. 2025 Dec;51(12):110481.
  30. Konishi T, Funayama N, Sunaga D, Ohori K, Yamamoto T, Kashiwagi Y, Hotta D, Yamazaki K, Nishihara H, Tanaka S. Pathological characteristics of aspirated thrombi from coronary artery embolism in patients with acute myocardial infarction. Cureus. 2025 Nov 9;17(11):e96443.

症例報告

  1. Murata Y, Kosaka T, Nakamura K, Baba Y, Arai E, Yasumizu Y, Matsumoto K, Nishihara H, Oya M. A case of testicular dysgenesis syndrome with squamous cell carcinoma of the prostate harboring a CDK12 mutation. IJU Case Rep. 2025 Jan 2;8(2):125-128.
  2. Ito K, Nakamura K, Kajihara T, Shinozaki Y, Imura J, Sakuma H. Coexistence of complete intestinal tract, prostatic tissue, prostatic urethra and bladder structure in ovarian mature cystic teratoma: a case report. Med Mol Morphol. 2025 Mar;58(1)91.
  3. So E, Ishida N, Chida A, Horie S, Kishimoto S, Tsugaru K, Hayashi H, Koda Y, Ozaki M, Okita H, Kanai T, Hirata K. A rare case of ALK-positive histiocytosis with neurological involvement in a 70-year-old woman successfully managed with partial resection and alectinib. Int Cancer Conf J. 2025 Jun 3;14(3):327-334.
  4. Fukunaga N, Terai H, Nomura R, Kurebayashi Y, Nakamura K, Kawano R, Shigeta K, Okabayashi K, Kinoshita K, Ogata A, Shigematsu L, Ito F, Takaoka H, Fukushima T, Nukaga S, Ohgino K, Yasuda H, Nishihara H, Kitagawa Y, Fukunaga K. Acquisition of FGFR1 and NSD3 amplifications during the transformation of EGFR-mutated lung adenocarcinoma into squamous cell carcinoma: a case report. JTO Clin Res Rep. 2025 Jun 13;6(9):100862.
  5. Koyanagi A, Kakumoto A, Kuroda H, Baba S, Koketsu M, Harada O, Kato Y, Nishihara H, Kawami H. A Case of false-negative results in the one-step nucleic acid amplification assay for sentinel lymph node metastasis in breast cancer with low cytokeratin 19 expression. Case Rep Oncol. 2025 Jul 2;18(1):1074-1080.
  6. Haraguchi Hashiguchi M, Tanino M, Yoneda S, Asaoka M, Kagyo J, Katayama M, Terai H, Nakamura K, Nishihara H, Fukunaga K. Acquired MTAP loss following Entrectinib resistance in ROS1-rearranged NSCLC with CD74 exon 3-ROS1 exon 34 fusion. Thorac Cancer. 2025 Oct;16(20):e70176.
  7. Karasawa H, Kosaka T, Komatsuda A, Baba Y, Nakamura K, Nishihara H, Oya M. Incidentally detected ductal adenocarcinoma presenting with isolated pulmonary metastasis and a BRCA2 mutation. IJU Case Rep. 2025 Nov 10;9(1):e70103.

アクセス・お問い合わせ

慶應義塾大学医学部
がんゲノム医療センター
腫瘍センター がんゲノム医療ユニット

〒160-8582 東京都新宿区信濃町 35
03-3353-1211 (代表)

Copyright 2024 Center for Cancer Genomics/Genomics Unit,Keio Cancer Center,Keio University School of Medicine, All Rights Reserved.